Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Oops, misread your message, sorry..
If enough of us ask about it, people will start responding
http://community.racingone.com/forums/56507ec8-7843-47b0-a6a7-ffb34fda10ab
Merry Christmas everyone... thank god for Mr. Lehner and Nascar
Lol, good work, that is classic :)
Form 8-K for AETHLON MEDICAL INC
19-Dec-2008
Change in Directors or Principal Officers
ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.
On December 15, 2008, the Company entered into an agreement with James
A. Joyce, the Company's Chairman, President, Chief Executive Officer, Chief Financial Officer and Secretary, pursuant to which the Company granted Mr. Joyce a non-statutory stock option to acquire an aggregate of 2,000,000 shares of the Company's common stock at an exercise price of $0.25 per share. The exercise price was set based on the closing price of the Company's common stock on November 13, 2008, the date on which the Company's Board of Directors approved the grant of the option. The option vested on December 15, 2008, the date of grant, with respect to 1,000,000 shares, will vest as to 500,000 shares on December 31, 2009 and will vest as to the remaining 500,000 shares on December 31, 2010. Unless terminated earlier in accordance with the agreement, the option, to the extent unexercised, will expire on November 13, 2018.
On December 15, 2008, the Company entered into separate agreements with Franklyn S. Barry and Edward G. Broenniman, two of the Company's non-employee directors, pursuant to which the Company granted to each such director a non-statutory stock option to acquire an aggregate of 500,000 shares of the Company's common stock at an exercise price of $0.41 per share. The exercise price was set based on the closing price of the Company's common stock on June 4, 2008, the date on which the Company's Board of Directors approved the grant of each option. In the case of each grant, the option vested on December 15, 2008, the date of grant, with respect to 333,333 shares and will vest as to the remaining 166,667 shares on June 4, 2009. Unless terminated earlier in accordance with its respective agreement, each option, to the extent unexercised, will expire on June 4, 2018.
In addition, on December 15, 2008, the Company entered into an agreement with Richard H. Tullis, Vice President, Chief Science Officer and a director of the Company, pursuant to which the Company granted to Mr. Tullis a non-statutory stock option to acquire an aggregate of 750,000 shares of the Company's common stock at an exercise price of $0.41 per share. The exercise price was set based on the closing price of the Company's common stock on June 4, 2008, the date on which the Company's Board of Directors approved the grant of the option. The option will vest as to 250,000 on June 4, 2009, 250,000 shares on June 4, 2010 and to the remaining 250,000 shares on June 4, 2011. Unless terminated earlier in accordance with the agreement, the option, to the extent unexercised, will expire on June 4, 2018.
The foregoing description of the options granted to Mr. Joyce, Mr. Barry, Mr. Broenniman and Mr. Tullis does not purport to be complete and is qualified in its entirety by their respective Stock Option Agreements, attached hereto as Exhibits 10.1, 10.2, 10.3 and 10.4, respectively, each of which is incorporated herein by reference.
On November 21, 2008, Mr. Harold Handley was terminated from his position as President of the Company. At this time, no replacement has been made. Mr. Handley's primary role with the Company was regulatory oversight. The Company plans to utilize consulting firms specializing in regulatory matters for the near future.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(d) EXHIBITS
EXHIBIT NO. DESCRIPTION
----------- -----------
10.1 Stock Option Agreement of James A. Joyce
10.2 Stock Option Agreement of Franklyn S. Barry
10.3 Stock Option Agreement of Edward G. Broenniman
10.4 Stock Option Agreement of Richard H. Tullis
Anyone know anything about this headline?
NEWS | SAN DIEGO
Aethlon lays off president
By REBECCA GO, The Daily Transcript
Friday, December 19, 2008
Aethlon Medical Inc. (OTC: AEMD) has laid off its president and will turn to outside firms to fill his role within the company, according to a Friday filing with the Securities and Exchange Commission.
That's all I can find....
Wish I could say that was me :)
I believe that's what it says, depending on commercialization in India... sotckpiling for next years' Dengue outbreak? I love it! The stockpiling, not the Dengue... ;)
Awesome coverage of AEMD!!!
http://www.therobinsgroup.biz/files/12_03_08_AEMD_IC.pdf
Looks like a very professional website! ;) Maybe we should emulate it..
Here's another competitor:
http://www.identityguard.com/
And another:
http://www.protectmyid.com/
We just need a small slice of the market to set the fire, IMO
That's great, more revenue for them to report when they do! Hopefully more people look past that or they fix it sooner than later.
Nice close all... I AM long, despite having to repeat myself several times. There's a lot of positive stuff going on here typos aside.
ALL I am saying is that I wouldn't want my SSN in the hands of this company as a customer, and from an investment side, (unfortunately) a lot of people's DD starts and ends with looking at the website. I've done more than that, however, and would still feel comfortable with the investment provided they fix the simple, yet extremely obvious mistakes. It's all about presentation.
We've been beating a dead horse, yes, so I'll stop talking about it as soon as one of the (on topic) messages doesn't get deleted :) Some poeple aren't ONLY looking for momentum.
I'm not so much concerned about the typos themselves as I am concerned that the company itself didn't seem to care enough to catch them before publishing the site.
Hopefully there are no mistakes when they're dealing with your SSN ;)
I didn't hear about it on Ihub... in fact, I first came to Ihub because I was googling "WNBD" so often that the ihub messages started to show up.
Would you sign up for their services as a customer?
lol, good call...
I want to make a profit here, I whacked the ask for 100K earlier to add to my position. That being said, having a professional looking website, especially for their kind of services, is a MUST, imo.. and easy to correct.
Guess it depens on where your money is, right?
Posted by: My 2 Cents Date: Thursday, November 20, 2008 11:29:47 AM
In reply to: MOMO who wrote msg# 186045 Post # of 186061
I know this is picky, but they need to fix the typo's before anyone's going to take them seriously enough to trust them with protecting their info:
"Guard Dog ID Identity Protection
The best protection for your identity is proactive notification when any credit related activity occurs. 's notification service monitors credit bureaus and online databases 24 hours a day, 365 days a year. By telling you when your credit is used, Guard Dog ID places you in control of your identity since you are forewarned the minute anyone attempts to use your name.
Guard Dog ID Identity Protection
- $14.95"
I noticed the same thing and agree... silly errors won't instill trust in potential clients.
Am I wrong about this or would it be to WNBD's benefit to have a buyback coincide (or come just before) the announcement of the NA?
You should ask him, you seem to be the only one questioning it anyway.
11's getting hit?
Not filling at .0011
I know this is picky, but they need to fix the typo's before anyone's going to take them seriously enough to trust them with protecting their info:
"Guard Dog ID Identity Protection
The best protection for your identity is proactive notification when any credit related activity occurs. 's notification service monitors credit bureaus and online databases 24 hours a day, 365 days a year. By telling you when your credit is used, Guard Dog ID places you in control of your identity since you are forewarned the minute anyone attempts to use your name.
Guard Dog ID Identity Protection
- $14.95"
Volume picking up
Helllooooo....Anyone have a good pick out there in this ugly market!? Holy crap.
Morning all.. PURO's got me excited for the day
I know this is a crude measure, but based on the dates of those PR's I'd say we're due for another :D
Interview with Daryl from Feb:
http://stockreport.smallcapvoice.com/audio.php?include=135100
Sticky updated... looking forward to tomorrow morning.
From the new 10Q:
PLAN OF OPERATION
We are a development stage medical device company that has not yet engaged in
significant commercial activities. The primary focus of our resources is the
advancement of our proprietary Hemopurifier(R) platform treatment technology,
which is designed to rapidly reduce the presence of infectious viruses and
toxins in human blood. Our focus is to prepare our Hemopurifier(R) to treat
chronic viral conditions, acute viral conditions and viral-based bioterror
threats in human clinical trials.
We plan to continue research and development activities related to our
Hemopurifier(R) platform technology, with particular emphasis on the advancement
of our treatment for "Category A" pathogens as defined by the Federal Government
under Project Bioshield and the All Hazards Preparedness Act of 2006. The
Company has filed an Investigational Device Exemption ("IDE") with the FDA in
order to proceed with Human safety studies of the Hemopurifier(R). Such studies,
complemented by planned IN VIVO and appropriate animal IN VITRO studies should
allow us to proceed to the Premarket Approval ("PMA") process. The PMA process
is the last major FDA hurdle in determining the safety and effectiveness of
Class III medical Devices (of which the Hemopurifier(R) is one).
Subject to the availability of working capital, we anticipate continuing to
increase spending on research and development over the next 12 months.
Additionally, associated with our anticipated increase in research and
development expenditures, we anticipate purchasing additional amounts of
equipment during this period to support our laboratory and testing operations.
Operations to date have consumed substantial capital without generating
revenues, and will continue to require substantial and increasing capital funds
to conduct necessary research and development and pre-clinical and clinical
testing of our Hemopurifier(R) products, as well as market any of those products
that receive regulatory approval. We do not expect to generate revenue from
operations for the foreseeable future, and our ability to meet our cash
obligations as they become due and payable is dependent for at least the next
several years on our ability to sell securities, borrow funds or a combination
thereof. Future capital requirements will depend upon many factors, including
progress with pre-clinical testing and clinical trials, the number and breadth
of our clinical programs, the time and costs involved in preparing, filing,
prosecuting, maintaining and enforcing patent claims and other proprietary
rights, the time and costs involved in obtaining regulatory approvals, competing
technological and market developments, as well as our ability to establish
collaborative arrangements, effective commercialization, marketing activities
and other arrangements. We expect to continue to incur increasing negative cash
flows and net losses for the foreseeable future.
Awesome AH news.. what we've been waiting for. Great buying opportunity under .1!
Yeah, I guess amazing results from studies proving the effectiveness of a revolutionary, first in class treatment with almost infinite applications is fluff... I can see that... ;)
Agreed. Puro is a good play.
Try .0002 :)
Thanks to the asst. mods who have been doing all the work!
Good work everyone! I'll be posting more here soon, looking forward to sharing in the excitement :) For now, back to work...
No problem, now just keep up the good work so you don't lose any :)